Celgene

Big Pharma come together for better drug side effect detection
Big Pharma come together for better drug side effect detection
Pharma Times
side effects
adverse events
Pfizer
Roche
Takeda
Eli Lilly
Bristol-Myers Squibb
Gilead Sciences
Alexion
Celgene
International Working Group on Signal Detection and Management in Pharmacovigilance
pharmacovigilance
Flag link:
Celgene and Acceleron Submit BLA for Luspatercept
Celgene and Acceleron Submit BLA for Luspatercept
CP Wire
Celgene
Acceleron
luspatercept
myelodysplastic syndrome
beta thalassemia
Flag link:
Celgene and Acceleron Submit BLA for Luspatercept
Celgene
Acceleron
luspatercept
Flag link:
Bristol-Myers' big Celgene buyout showers $187M-plus on Morgan Stanley
Bristol-Myers' big Celgene buyout showers $187M-plus on Morgan Stanley
Endpoints
Bristol-Myers Squibb
Celgene
Morgan Stanley
M&A
Flag link:
After winning key support for Celgene buyout, Bristol-Myers CEO Caforio emerges as clear likely winner in looming shareholder vote
After winning key support for Celgene buyout, Bristol-Myers CEO Caforio emerges as clear likely winner in looming shareholder vote
Endpoints
Bristol-Myers Squibb
Celgene
M&A
Starboard
Giovanni Caforio
Flag link:
Bristol-Myers scores a critical endorsement for its embattled Celgene merger
Bristol-Myers scores a critical endorsement for its embattled Celgene merger
Stat
Bristol-Myers Squibb
Celgene
M&A
Flag link:
Celgene refiles ozanimod with FDA 1 year after regulatory snafu
Celgene refiles ozanimod with FDA 1 year after regulatory snafu
Fierce Biotech
Celgene
ozanimod
MS
multiple sclerosis
Flag link:
Bristol-Myers Gets FTC Request for More Information on $74 Billion Celgene Deal
Bristol-Myers Gets FTC Request for More Information on $74 Billion Celgene Deal
TheStreet.com
SEC
FTC
M&A
Bristol-Myers Squibb
Celgene
Flag link:
Could proxy advisors sway investors to vote ‘no’ on BMS-Celgene merger?
Could proxy advisors sway investors to vote ‘no’ on BMS-Celgene merger?
Fierce Pharma
Bristol-Myers Squibb
Celgene
investors
M&A
Flag link:
Celgene taps Exscientia’s AI drug discovery tech for 3 new programs
Celgene taps Exscientia’s AI drug discovery tech for 3 new programs
Fierce Biotech
Celgene
Exscientia
artificial intelligence
oncology
autoimmune disease
drug discovery
Flag link:
Bristol-Myers and Starboard Value spar over $74B Celgene buyout as shareholder vote looms
Bristol-Myers and Starboard Value spar over $74B Celgene buyout as shareholder vote looms
Endpoints
Bristol-Myers Squibb
Starboard
Celgene
M&A
Flag link:
UK gets early access to Roche’s breast cancer immunotherapy
UK gets early access to Roche’s breast cancer immunotherapy
Pharmaforum
Roche
Tecentriq
Celgene
Abraxane
UK
triple-negative breast cancer
Flag link:
Is Celgene and Bristol-Myers a Match Made in Heaven or Doomed to Fail?
Is Celgene and Bristol-Myers a Match Made in Heaven or Doomed to Fail?
Motley Fool
M&A
Bristol-Myers Squibb
Celgene
Flag link:
U.S. court rejects Alvogen's patent challenge for Celgene's cancer drug
U.S. court rejects Alvogen's patent challenge for Celgene's cancer drug
Yahoo/Reuters
Celgene
Revlimid
patents
Multiple Myeloma
Alvogen
Flag link:
Celgene’s Abraxane Fails to Hit the Mark in a Phase III Pancreatic Cancer Study
Celgene’s Abraxane Fails to Hit the Mark in a Phase III Pancreatic Cancer Study
BioSpace
Celgene
Abraxane
clinical trials
pancreatic cancer
Flag link:
How This Looming Patent Battle Could Challenge Bristol-Celgene Deal
How This Looming Patent Battle Could Challenge Bristol-Celgene Deal
Investors Business Daily
Celgene
Novartis
ozanimod
MS
multiple sclerosis
patents
Bristol-Myers Squibb
M&A
Flag link:
Bristol-Myers CEO Caforio wants M&A dissidents to know there's been no 'high level' overtures about buying the company since '17
Bristol-Myers CEO Caforio wants M&A dissidents to know there's been no 'high level' overtures about buying the company since '17
Endpoints
Bristol-Myers Squibb
Celgene
Giovanni Caforio
M&A
Flag link:
Celgene Submits MS Drug for Approval in Europe, FDA Filing on Track
Celgene Submits MS Drug for Approval in Europe, FDA Filing on Track
Xconomy
Celgene
Bristol-Myers Squibb
Europe
FDA
M&A
MS
multiple sclerosis
ozanimod
Flag link:
Does Bristol-Myers have a plan B if activists scuttle its Celgene buy?
Does Bristol-Myers have a plan B if activists scuttle its Celgene buy?
Fierce Pharma
Bristol-Myers Squibb
Celgene
M&A
Flag link:
It’s what Bristol-Myers execs aren’t saying that makes one key analyst wonder about a potential buyout offer, looming Opdivo data and Plan B
It’s what Bristol-Myers execs aren’t saying that makes one key analyst wonder about a potential buyout offer, looming Opdivo data and Plan B
Endpoints
Bristol-Myers Squibb
Celgene
M&A
Opdivo
Flag link:

Pages